NO

NovMetaPharma Co., Ltd.

Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.

229500 | KO

Overview

Corporate Details

ISIN(s):
KR7229500004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 727 13층 (논현동, 트리스빌딩), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research, development, and commercialization of first-in-class drugs for metabolic and fibrotic diseases. The company focuses on creating novel treatments with differentiated mechanisms to address significant unmet medical needs. Its core pipeline includes therapeutic candidates for conditions such as type 2 diabetes, obesity, chronic kidney disease, and fibrosis, with lead assets including Cyclo-Z and CHP. In addition to its primary focus on drug development, the company also develops health supplements and sells related raw materials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-15 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-13 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 4.8 KB
2025-04-29 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-03-31 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 170.5 KB
2025-03-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.3 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.3 KB
2025-03-24 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 22.1 KB
2025-03-14 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 361.6 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 9.4 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.0 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 238.9 KB
2025-03-06 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 66.1 KB
2025-02-05 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 5.6 KB
2024-12-20 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.7 KB
2024-12-17 00:00
Regulatory News Service
특허권취득(자율공시)
Korean 6.1 KB

Automate Your Workflow. Get a real-time feed of all NovMetaPharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NovMetaPharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NovMetaPharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.